ArticleAdvances in radiation oncology2026
Pan-Cancer Gene Expression Predicts Per-Cancer Radiation Therapy Response.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Although radiation therapy response involves biological processes shared across cancers, most biomarker studies rely on small, disease-specific sample sizes that limit the reliability of prognostic models. This study evaluated whether pan-cancer data can increase the information available for estimating genomic associations with progression after radiation therapy, based on Molecular Signatures Database hallmark gene sets applied to The Cancer Genome Atlas patients. Methods and Materials: Cross-cancer predictive potential was evaluated in cancer types with at least 100 patients who received radiation therapy and had information on gene expression, progression, age, stage, and gender: breast invasive carcinoma (n = 553), cervical squamous cell carcinoma (n = 183), head-neck squamous cell carcinoma (n = 320), low-grade glioma (n = 316), lung adenocarcinoma (n = 104), skin cutaneous melanoma (n = 125), thyroid cancer (n = 326), and uterine corpus endometrial carcinoma ( Results: In Kaplan-Meier analysis, pan-cancer scores predicted progression in all cancer types, with varying statistical significance. Univariable Cox proportional hazards models also demonstrated consistent association with progression, again with varying significance. Associations persisted when adjusted for clinical variables, and model performance metrics indicated the potential to improve per-cancer prognostication. Associations were particularly strong for breast invasive carcinoma, cervical squamous cell carcinoma, head-neck squamous cell carcinoma, low-grade glioma, and lung adenocarcinoma, with statistically insignificant results for skin cutaneous melanoma, thyroid cancer, and uterine corpus endometrial carcinoma. Conclusions: Pan-cancer gene expression data can predict per-cancer progression after radiation therapy, with variable strength across cancer types. These findings support the use of cross-cancer genomic information to address sample size limitations that affect radiation therapy biomarker development.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.